Literature DB >> 12882980

High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.

James J Fiordalisi1, Ronald L Johnson, Carolyn A Weinbaum, Kaoru Sakabe, Zhui Chen, Patrick J Casey, Adrienne D Cox.   

Abstract

Farnesyltransferase inhibitors (FTIs) block Ras farnesylation, subcellular localization and activity, and inhibit the growth of Ras-transformed cells. Although FTIs are ineffective against K-Ras4B, the Ras isoform most commonly mutated in human cancers, they can inhibit the growth of tumors containing oncogenic K-Ras4B, implicating other farnesylated proteins or suggesting distinct functions for farnesylated and for geranylgeranylated K-Ras, which is generated when farnesyltransferase is inhibited. In addition to bypassing FTI blockade through geranylgeranylation, K-Ras4B resistance to FTIs may also result from its higher affinity for farnesyltransferase. Using chimeric Ras proteins containing all combinations of Ras background, CAAX motif, and K-Ras polybasic domain, we show that either a polybasic domain or an alternatively prenylated CAAX renders Ras prenylation, Ras-induced Elk-1 activation, and anchorage-independent cell growth FTI-resistant. The polybasic domain alone increases the affinity of Ras for farnesyltransferase, implying independent roles for each K-Ras4B sequence element in FTI resistance. Using microarray analysis and colony formation assays, we confirm that K-Ras function is independent of the identity of the prenyl group and, therefore, that FTI inhibition of K-Ras transformed cells is likely to be independent of K-Ras inhibition. Our results imply that relevant FTI targets will lack both polybasic and potentially geranylgeranylated methionine-CAAX motifs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12882980     DOI: 10.1074/jbc.M305733200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Ras history: The saga continues.

Authors:  Adrienne D Cox; Channing J Der
Journal:  Small GTPases       Date:  2010-07

2.  The chaperone SmgGDS-607 has a dual role, both activating and inhibiting farnesylation of small GTPases.

Authors:  Desirée García-Torres; Carol A Fierke
Journal:  J Biol Chem       Date:  2019-06-13       Impact factor: 5.157

Review 3.  Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting.

Authors:  James V Michael; Lawrence E Goldfinger
Journal:  Semin Cancer Biol       Date:  2017-12-02       Impact factor: 15.707

4.  Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Authors:  David E Gerber; Mark A Socinski; Joel W Neal; Heather A Wakelee; Keisuke Shirai; Lecia V Sequist; Rachel P Rosovsky; Rogerio C Lilenbaum; Bruno R Bastos; Chao Huang; Melissa L Johnson; Paul J Hesketh; Deepa S Subramaniam; Martin F Dietrich; Feng Chai; Yunxia Wang; Julia Kazakin; Brian Schwartz; Joan H Schiller; Julie R Brahmer; Ronan J Kelly
Journal:  Lung Cancer       Date:  2018-02-03       Impact factor: 5.705

5.  Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras.

Authors:  Chris J Novotny; Gregory L Hamilton; Frank McCormick; Kevan M Shokat
Journal:  ACS Chem Biol       Date:  2017-06-19       Impact factor: 5.100

6.  Synthesis and screening of a CaaL peptide library versus FTase reveals a surprising number of substrates.

Authors:  Amanda J Krzysiak; Animesh V Aditya; James L Hougland; Carol A Fierke; Richard A Gibbs
Journal:  Bioorg Med Chem Lett       Date:  2009-11-12       Impact factor: 2.823

Review 7.  Pharmacological Inhibition of Protein Lipidation.

Authors:  Lakshmi Ganesan; Ilya Levental
Journal:  J Membr Biol       Date:  2015-08-18       Impact factor: 1.843

8.  Identification of a farnesol analog as a Ras function inhibitor using both an in vivo Ras activation sensor and a phenotypic screening approach.

Authors:  Kamalakkannan Srinivasan; Thangaiah Subramanian; H Peter Spielmann; Chris Janetopoulos
Journal:  Mol Cell Biochem       Date:  2013-11-06       Impact factor: 3.396

9.  The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.

Authors:  Sarah J O'Meara; B Therese Kinsella
Journal:  Biochem J       Date:  2005-02-15       Impact factor: 3.857

10.  Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification.

Authors:  Patrick J Roberts; Natalia Mitin; Patricia J Keller; Emily J Chenette; James P Madigan; Rachel O Currin; Adrienne D Cox; Oswald Wilson; Paul Kirschmeier; Channing J Der
Journal:  J Biol Chem       Date:  2008-07-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.